{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:31:44Z","timestamp":1793226704912,"version":"4.5.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.atherosclerosis.2026.121928","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:15:22Z","timestamp":1791587722000},"page":"121928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lp(a) reduction with PCSK9 inhibitors: How does real-world data stack up?"],"prefix":"10.1016","volume":"422","author":[{"given":"Karam","family":"Kostner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.atherosclerosis.2026.121928_bib1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.121928_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40256-020-00437-7","article-title":"Emerging pharmacotherapy to reduce elevated lipoprotein(a) plasma levels","volume":"21","author":"Eraikhuemen","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.atherosclerosis.2026.121928_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2026.121928_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11883-023-01113-2","article-title":"Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a)","volume":"25","author":"Safarova","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2026.121928_bib5","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1517\/14656566.9.16.2911","article-title":"Niacin: a lipid polypill?","volume":"9","author":"Kostner","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2026.121928_bib6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.121928_bib8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jacl.2026.03.019","article-title":"Lipoprotein(a) reduction with in liseran, alirocumab, evolucomab, enlicitide and lerodalcibep: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Mulligan","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.121928_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:34:53Z","timestamp":1793223293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026012943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":8,"alternative-id":["S0021915026012943"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121928","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a) reduction with PCSK9 inhibitors: How does real-world data stack up?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121928"}}